Citius Pharmaceuticals, Inc.CTXRNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+401.3%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
+401.3%/yr
Quarterly compound
Percentile
P100
Near historical high
vs 3Y Ago
126x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 382.24% |
| Q3 2025 | -83.45% |
| Q2 2025 | 49.55% |
| Q1 2025 | -11.06% |
| Q4 2024 | -33.78% |
| Q3 2024 | 3.37% |
| Q2 2024 | 6.87% |
| Q1 2024 | 9.61% |
| Q4 2023 | -7.22% |
| Q3 2023 | 47.57% |
| Q2 2023 | -17.64% |
| Q1 2023 | 56.62% |
| Q4 2022 | 3.03% |
| Q3 2022 | -8.34% |
| Q2 2022 | -2.66% |
| Q1 2022 | 8.87% |
| Q4 2021 | 30.68% |
| Q3 2021 | -23.06% |
| Q2 2021 | 43.40% |
| Q1 2021 | 34.16% |
| Q4 2020 | -25.92% |
| Q3 2020 | 29.74% |
| Q2 2020 | -15.41% |
| Q1 2020 | 35.54% |
| Q4 2019 | 8.77% |
| Q3 2019 | -1.26% |
| Q2 2019 | -14.50% |
| Q1 2019 | 10.39% |
| Q4 2018 | -8.54% |
| Q3 2018 | 55.25% |
| Q2 2018 | -13.17% |
| Q1 2018 | -45.87% |
| Q4 2017 | 36.74% |
| Q3 2017 | -6.61% |
| Q2 2017 | 22.61% |
| Q1 2017 | 22.57% |
| Q4 2016 | -7.39% |
| Q3 2016 | -15.01% |
| Q2 2016 | 100.17% |
| Q1 2016 | 109.84% |